MedPath

Prospective Randomized Controlled trial of low dose long term Peg-Interferon alpha-2a treatment after curative ablation for Hepatocellular Carcinoma

Not Applicable
Conditions
Chronic hepatitis C Hepatocellular carcinoma
Registration Number
JPRN-C000000323
Lead Sponsor
Department of Gastroenterology University of Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

Patient with 1.Drug allergy against Interferon. 2.Allergy against biological drugs. 3.Poorly controlled heart disease. 4.Extrahepatic metastasis of HCC 5.Active cancer of other organ. 6.Severe renal dysfunction; BUN>30mg/dL, or Cre>2.0mg/dL 7.on the herb treatment 8.other chronic liver disease like AIH or hepatitisB 9.Depression 10.on other clinical trial 11. any reason which medical doctor regard the patient as unsuitable for this test.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. HCC recurent rate 2. Time to recurrence
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath